Daily Digest
Daily Digest
Pomegra Startups
Deep tech startup news: biotech, robotics, hardware, energy, defence, and security companies - the capital-intensive bets with long horizons and hard science behind them.
UK air defense startup Cambridge Aerospace raises $300M Series C at a $3.4B valuation, backed by DFJ Growth and Accel, to scale its drone and missile interceptor products.
Autonomy testing startup Agon emerges from stealth with $30M across pre-seed and seed rounds to build validation software for self-driving and autonomous systems.
Canadian biotech Biossil exits stealth with $70M to repurpose previously failed drug compounds for new therapeutic indications.
Construction robotics startup Gritt exits stealth with $32M to deploy autonomous robots that build utility-scale solar farms.
Zurich-based Gravis Robotics raises $200M Series A from SoftBank at a $1B valuation to retrofit excavators and heavy construction equipment with autonomous AI systems.
Optical interconnect startup Lumilens emerges from stealth with $700M+ in Series C funding at a $5.51B valuation to solve GPU networking bottlenecks inside AI data centers.
Cybersecurity startup Glow raises $180M Series A at a $1.2B valuation, backed by Sequoia, Cyberstarts, Greenoaks, and Redpoint, to secure enterprise AI agent deployments.
Home battery startup Base Power raises $1B Series D at a $13B valuation, led by Ribbit and Valor Equity Partners, to expand residential grid-stabilizing battery deployment across the US.
Deep tech companies commercialise hard science rather than software alone: a new battery chemistry, a reactor design, a drug candidate, a robot that works outside a lab. What they share is a long, expensive path between the first cheque and the first revenue, because the risk being funded is whether the technology works at all, not whether customers want it. That changes how their rounds read - a large raise can mean a company is years from a product, not close to one.
That profile also makes deep tech the segment where private capital matters most. Public markets rarely fund a decade of pre-revenue research, so the important valuation events happen privately, and the eventual IPO or acquisition prices work that was already done. Coverage here groups biotech, robotics, hardware, energy, defence, and security together because they behave alike as investments, even when the science does not.
Because the risk being funded is technical. Clinical trials, reactor licensing, and hardware manufacturing all have timelines set by physics and regulators rather than by product iteration, so a decade between founding and exit is normal rather than a warning sign.
The failure modes differ. Deep tech can fail outright if the science does not work, but a company that succeeds often has durable advantages that are hard to copy. Software fails less absolutely and is competed away faster. This is educational context, not investment advice.
Pomegra